The Experts below are selected from a list of 16986 Experts worldwide ranked by ideXlab platform
Ozcan Erel - One of the best experts on this subject based on the ideXlab platform.
-
decreased Paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus
Journal of Womens Health, 2009Co-Authors: Hakan Camuzcuoglu, Harun Toy, Hale Cakir, Hakim Celik, Ozcan ErelAbstract:Abstract Objective: The aim of this study was to investigate serum Paraoxonase, arlyesterase activities, and lipid hydroperoxide (LOOH) levels in patients with gestational diabetes mellitus (GDM). Methods: Paraoxonase and arylesterase activities, and LOOH levels were assessed for GDM cases (n = 55) and controls (n = 59). Serum basal and salt-stimulated Paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by ferrous oxidation with a xylenol orange assay. Results: Basal and salt-stimulated Paraoxonase and arylesterase activities were significantly lower (p = 0.002, p = 0.004; and p = 0.013, respectively) in patients with GDM compared to controls, while LOOH levels were significantly higher (p < 0.001). Among gestational diabetes patients, serum Paraoxonase and arylesterase activities were inversely correlated with LOOH levels (r = − 0.390, p = 0.003; and r = − 0.287, p = 0.034, respectively). Conclusions: Findings of the present study have shown that serum ...
-
Decreased Paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus.
Journal of women's health (2002), 2009Co-Authors: Hakan Camuzcuoglu, Harun Toy, Hale Cakir, Hakim Celik, Ozcan ErelAbstract:Abstract Objective: The aim of this study was to investigate serum Paraoxonase, arlyesterase activities, and lipid hydroperoxide (LOOH) levels in patients with gestational diabetes mellitus (GDM). Methods: Paraoxonase and arylesterase activities, and LOOH levels were assessed for GDM cases (n = 55) and controls (n = 59). Serum basal and salt-stimulated Paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by ferrous oxidation with a xylenol orange assay. Results: Basal and salt-stimulated Paraoxonase and arylesterase activities were significantly lower (p = 0.002, p = 0.004; and p = 0.013, respectively) in patients with GDM compared to controls, while LOOH levels were significantly higher (p
-
Paraoxonase and arylesterase activities in untreated dipper and non dipper hypertensive patients
Clinical Biochemistry, 2008Co-Authors: Ali Yildiz, Mehmet Aslan, Recep Demirbag, Mustafa Gur, Remzi Yilmaz, Selahattin Akyol, Ozcan ErelAbstract:Objectives Paraoxonase, a high density lipoprotein (HDL) associated enzyme, was shown to be reduced in patients with cardiovascular diseases. We aimed to examine serum Paraoxonase and arylesterase activities, and oxidative stress markers such as lipid hydroperoxide (LOOH) and total antioxidant status (TAS) in dipper and non-dipper hypertensive patients. Design and methods Forty-six non-dipper hypertensives (NDH group), 40 dipper hypertensives (DH group) and 28 healthy control subjects were included in the study. Clinical and echocardiographic assessment and ambulatory blood pressure monitoring were performed in all subjects. Serum Paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by ferrous oxidation with xylenol orange assay. TAS was determined by using an automated measurement method. Results Paraoxonase and arylesterase activities and TAS levels were significantly lower in patients with NDH compared to both DH and control groups (p < 0.001, for both). Also, LOOH levels were found at high level in patients with NDH compared to control and DH groups. In NDH group, both Paraoxonase and arylesterase activities were independently correlated with LDL cholesterol, TAS and LOOH levels. In DH group, both Paraoxonase and arylesterase activities were independently correlated with HDL cholesterol and LOOH levels. Conclusions Reduced Paraoxonase and arylesterase activities in NDH might indicate increased oxidative stress, which plays an important role in the development of cardiovascular diseases. Low serum activities of Paraoxonase and arylesterase might be considered as prospective prognostic markers of the development of cardiovascular diseases in dipper and non-dipper hypertensive patients.
-
Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients.
Clinical biochemistry, 2008Co-Authors: Ali Yildiz, Mehmet Aslan, Recep Demirbag, Mustafa Gur, Remzi Yilmaz, Selahattin Akyol, Ozcan ErelAbstract:Paraoxonase, a high density lipoprotein (HDL) associated enzyme, was shown to be reduced in patients with cardiovascular diseases. We aimed to examine serum Paraoxonase and arylesterase activities, and oxidative stress markers such as lipid hydroperoxide (LOOH) and total antioxidant status (TAS) in dipper and non-dipper hypertensive patients. Forty-six non-dipper hypertensives (NDH group), 40 dipper hypertensives (DH group) and 28 healthy control subjects were included in the study. Clinical and echocardiographic assessment and ambulatory blood pressure monitoring were performed in all subjects. Serum Paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by ferrous oxidation with xylenol orange assay. TAS was determined by using an automated measurement method. Paraoxonase and arylesterase activities and TAS levels were significantly lower in patients with NDH compared to both DH and control groups (p<0.001, for both). Also, LOOH levels were found at high level in patients with NDH compared to control and DH groups. In NDH group, both Paraoxonase and arylesterase activities were independently correlated with LDL cholesterol, TAS and LOOH levels. In DH group, both Paraoxonase and arylesterase activities were independently correlated with HDL cholesterol and LOOH levels. Reduced Paraoxonase and arylesterase activities in NDH might indicate increased oxidative stress, which plays an important role in the development of cardiovascular diseases. Low serum activities of Paraoxonase and arylesterase might be considered as prospective prognostic markers of the development of cardiovascular diseases in dipper and non-dipper hypertensive patients.
-
serum Paraoxonase and arylesterase activities for the evaluation of patients with chronic hepatitis
International Journal of Clinical Practice, 2007Co-Authors: Mehmet Aslan, Mehmet Horoz, Sahbettin Selek, Yasar Nazligul, Cengiz Bolukbas, Filiz F Bolukbas, Nurten Aksoy, Ozcan ErelAbstract:Summary The sensitivity of standard biochemical tests for liver function is low and insufficient for a reliable determination of the presence or absence of liver disease. The aim of the present study was to investigate serum Paraoxonase and arylesterase activities and lipid hydroperoxide (LOOH) levels, and to find out that whether the measurement of serum Paraoxonase and arylesterase activities would be useful as an index of liver function status in chronic hepatitis (CH). Fourty-four patients with CH (24 CHB and 20 CHC) and 38 controls were enrolled. Serum Paraoxonase and arylesterase activities were detected spectrophotometrically. LOOH levels were measured by the FOX-2 assay. Serum Paraoxonase and arylesterase activities were significantly lower in patients with CH than controls (p < 0.001 for both), while LOOH levels were significantly higher (p < 0.001). Paraoxonase and arylesterase activities were inversely correlated with LOOH levels (r = −0.394, p < 0.05; r =−0.362, p < 0.05, respectively). Fibrosis scores of CH patients were significantly correlated with Paraoxonase and arylesterase activities and LOOH levels (r =−0.276, p < 0.05; r = −0.583, p < 0.001 and r = 0.562, p < 0.001, respectively). Our results indicated that decrease in the activities Paraoxonase and arylesterase may play a role in the pathogenesis of CH. In addition, serum Paraoxonase and arylesterase activities measurement may add a significant contribution to the liver function tests.
Michael I Mackness - One of the best experts on this subject based on the ideXlab platform.
-
serum Paraoxonase 1 activity and concentration are influenced by human immunodeficiency virus infection
Atherosclerosis, 2007Co-Authors: Sandra Parra, Michael I Mackness, Bharti Mackness, Natalia Ferre, Judit Marsillach, Carlos Alonsovillaverde, Blai Coll, Gerard Aragones, L Masana, Jorge JovenAbstract:Abstract Background Higher high-density lipoprotein concentrations are associated with a better disease course in HIV-infected patients. Paraoxonase-1, an enzyme contained within high-density lipoproteins, is thought to hydrolyse oxidised lipids. The aim of the present study was to investigate the relationships between HIV infection and the circulating activity and concentration of Paraoxonase-1, and the concentration of high-density lipoproteins, apolipoprotein A-I and oxidised low-density lipoproteins. Methods We studied patients with HIV infection ( n =212) and healthy subjects ( n =409). In all the participants we measured the relevant biochemical and genetic variables. The statistical associations between these variables and Paraoxonase-1 activity and concentration were assessed using multiple linear regression analysis. Results Serum Paraoxonase-1 activity was decreased ( P P =0.017) in HIV-patients compared to the controls. HIV infected patients had lower HDL-cholesterol and apolipoprotein A-I concentrations. Multivariate regression analysis showed that serum Paraoxonase-1 activity was associated with the CD4+ T lymphocyte count ( P P P P Conclusions Both, Paraoxonase-1 activity and concentration were influenced by HIV-infection and these were related to alterations in HDL composition and the immunological status of the patients.
-
Serum Paraoxonase-1 in chronic alcoholics: relationship with liver disease.
Clinical Biochemistry, 2007Co-Authors: Judit Marsillach, Michael I Mackness, Bharti Mackness, Natalia Ferre, María Vila, Anna Lligoña, Ramon Deulofeu, Ricard Solà, Albert Parés, Juan Pedro-botetAbstract:Objectives: To investigate the relationship between serum Paraoxonase-1 and liver damage in chronic alcoholic patients. To assess the diagnostic accuracy of Paraoxonase-1 plus standard biochemical tests in the assessment of liver damage in alcoholics. Design and methods: We studied 328 chronic alcoholics and 368 healthy individuals. Results: Paraoxonase-1 activity was decreased and the concentration was increased in alcoholics (P
-
The Paraoxonase gene family and coronary heart disease.
Current opinion in lipidology, 2002Co-Authors: Bharti Mackness, Paul N Durrington, Michael I MacknessAbstract:Purpose of review The antioxidant activity of high-density lipoprotein is largely due to the Paraoxonase 1 located on it. Experiments with transgenic Paraoxonase 1 knock-out mice indicate the potential for this enzyme to protect against atherogenesis. This effect of high-density lipoprotein in decreasing low-density lipoprotein lipid peroxidation is maintained for longer than that of antioxidant vitamins and could thus be more protective. Several important advances in the field of Paraoxonase research have occurred during this review period, not least the discovery that two other members of the Paraoxonase gene family, PON2 and PON3, may also have important antioxidant properties. Significant advances have been made in understanding the basic biochemical function of Paraoxonase 1 and the discovery of possible modulators of its activity. Recent findings Decreased coronary heart disease risk associated with polymorphisms of Paraoxonase 1, which are most active in lipid peroxide hydrolysis, as revealed by meta-analysis is likely to be an underestimate of the true contribution of Paraoxonase 1 to coronary heart disease because these polymorphisms explain only a small component of the variation in Paraoxonase 1 activity. It is a very important observation, however, because genetic influences are not likely to be confounded by other factors linked with both coronary heart disease and diminished Paraoxonase 1 activity. Summary Although advances have been made in research into the Paraoxonase family and atherosclerosis, much more needs to be done. Paraoxonase 1 is much the most extensively researched and strategies will hopefully emerge to increase its activity and provide a more satisfactory test of the antioxidant hypothesis of atherosclerosis than antioxidant vitamins have done.
-
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins.
Current opinion in lipidology, 1996Co-Authors: Michael I Mackness, Paul N Durrington, Bharti Mackness, Philip W. Connelly, Robert A. HegeleAbstract:Human serum Paraoxonase is located on an HDL. It has the capacity to retard the accumulation of lipid peroxides in LDL under oxidizing conditions in vitro. Paraoxonase has a genetic polymorphism that results in a single amino acid substitution. Evidence indicates that both the serum concentration of Paraoxonase and an individual's genotype are related to plasma lipid and lipoprotein concentrations, and possibly also to coronary heart disease, implicating Paraoxonase in the development of atherosclerosis.
-
serum Paraoxonase activity concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins
Arteriosclerosis Thrombosis and Vascular Biology, 1995Co-Authors: C A Abbott, Michael I Mackness, Sudhesh Kumar, Andrew J M Boulton, Paul N DurringtonAbstract:Human serum Paraoxonase is physically associated with HDL and has been implicated in the detoxification of organophosphates and possibly in the prevention of LDL lipid peroxidation. We investigated the serum activity and concentration of Paraoxonase in 78 patients with type 1 diabetes mellitus, 92 with type 2 diabetes, and 82 nondiabetic control subjects. Paraoxonase activity was generally lower in diabetics than in control subjects. This decrease was unrelated to differences in Paraoxonase phenotype distribution or its serum concentration. Rather, the difference in Paraoxonase activity was explained by its specific activity, which was lower in diabetics, indicating either the presence of a circulating inhibitor or disturbance of the interaction of Paraoxonase with HDL affecting its activity. Paraoxonase specific activity was lowest in patients with peripheral neuropathy, suggesting an association of Paraoxonase with neuropathy. In control subjects but not patients with diabetes, Paraoxonase correlated with HDL cholesterol and apolipoprotein A-1. Our results indicate that the low Paraoxonase activity in diabetes is due to decreased specific activity. In other studies low serum Paraoxonase activity has been associated with increased susceptibility to atherosclerosis, and the present results also suggest an association with peripheral neuropathy, which could be due to reduced capacity to detoxify lipid peroxides in diabetes.
Paul N Durrington - One of the best experts on this subject based on the ideXlab platform.
-
The Paraoxonase gene family and coronary heart disease.
Current opinion in lipidology, 2002Co-Authors: Bharti Mackness, Paul N Durrington, Michael I MacknessAbstract:Purpose of review The antioxidant activity of high-density lipoprotein is largely due to the Paraoxonase 1 located on it. Experiments with transgenic Paraoxonase 1 knock-out mice indicate the potential for this enzyme to protect against atherogenesis. This effect of high-density lipoprotein in decreasing low-density lipoprotein lipid peroxidation is maintained for longer than that of antioxidant vitamins and could thus be more protective. Several important advances in the field of Paraoxonase research have occurred during this review period, not least the discovery that two other members of the Paraoxonase gene family, PON2 and PON3, may also have important antioxidant properties. Significant advances have been made in understanding the basic biochemical function of Paraoxonase 1 and the discovery of possible modulators of its activity. Recent findings Decreased coronary heart disease risk associated with polymorphisms of Paraoxonase 1, which are most active in lipid peroxide hydrolysis, as revealed by meta-analysis is likely to be an underestimate of the true contribution of Paraoxonase 1 to coronary heart disease because these polymorphisms explain only a small component of the variation in Paraoxonase 1 activity. It is a very important observation, however, because genetic influences are not likely to be confounded by other factors linked with both coronary heart disease and diminished Paraoxonase 1 activity. Summary Although advances have been made in research into the Paraoxonase family and atherosclerosis, much more needs to be done. Paraoxonase 1 is much the most extensively researched and strategies will hopefully emerge to increase its activity and provide a more satisfactory test of the antioxidant hypothesis of atherosclerosis than antioxidant vitamins have done.
-
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins.
Current opinion in lipidology, 1996Co-Authors: Michael I Mackness, Paul N Durrington, Bharti Mackness, Philip W. Connelly, Robert A. HegeleAbstract:Human serum Paraoxonase is located on an HDL. It has the capacity to retard the accumulation of lipid peroxides in LDL under oxidizing conditions in vitro. Paraoxonase has a genetic polymorphism that results in a single amino acid substitution. Evidence indicates that both the serum concentration of Paraoxonase and an individual's genotype are related to plasma lipid and lipoprotein concentrations, and possibly also to coronary heart disease, implicating Paraoxonase in the development of atherosclerosis.
-
serum Paraoxonase activity concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins
Arteriosclerosis Thrombosis and Vascular Biology, 1995Co-Authors: C A Abbott, Michael I Mackness, Sudhesh Kumar, Andrew J M Boulton, Paul N DurringtonAbstract:Human serum Paraoxonase is physically associated with HDL and has been implicated in the detoxification of organophosphates and possibly in the prevention of LDL lipid peroxidation. We investigated the serum activity and concentration of Paraoxonase in 78 patients with type 1 diabetes mellitus, 92 with type 2 diabetes, and 82 nondiabetic control subjects. Paraoxonase activity was generally lower in diabetics than in control subjects. This decrease was unrelated to differences in Paraoxonase phenotype distribution or its serum concentration. Rather, the difference in Paraoxonase activity was explained by its specific activity, which was lower in diabetics, indicating either the presence of a circulating inhibitor or disturbance of the interaction of Paraoxonase with HDL affecting its activity. Paraoxonase specific activity was lowest in patients with peripheral neuropathy, suggesting an association of Paraoxonase with neuropathy. In control subjects but not patients with diabetes, Paraoxonase correlated with HDL cholesterol and apolipoprotein A-1. Our results indicate that the low Paraoxonase activity in diabetes is due to decreased specific activity. In other studies low serum Paraoxonase activity has been associated with increased susceptibility to atherosclerosis, and the present results also suggest an association with peripheral neuropathy, which could be due to reduced capacity to detoxify lipid peroxides in diabetes.
-
protection of low density lipoprotein against oxidative modification by high density lipoprotein associated Paraoxonase
Atherosclerosis, 1993Co-Authors: Michael I Mackness, C A Abbott, S Arrol, Paul N DurringtonAbstract:We have investigated the Cu2+ induced generation of lipid peroxides in low density lipoprotein (LDL) incubated with high density lipoprotein (HDL) and with purified Paraoxonase, an enzyme normally resident on HDL. HDL (1.5 mg) and Paraoxonase (20 micrograms) inhibited lipid peroxide generation in LDL by 32% and 25%, respectively after 24 h of incubation (both P < 0.01). The decrease in LDL lipid peroxides both with HDL and with Paraoxonase were concentration dependent. The degree of protection offered by HDL tended to relate to its Paraoxonase activity (R = 0.47; P < 0.06). Neither purified Paraoxonase nor HDL chelated Cu2+ sufficiently to account for the decrease in LDL oxidation. Purified Paraoxonase did not affect LDL oxidation when it had been heat inactivated. Mass transfer of lipid peroxides from LDL to HDL did not explain the protection of LDL against oxidation: the total lipid peroxides accumulating during incubation was decreased both by HDL and by Paraoxonase. These results suggest a direct role for HDL in preventing atherosclerosis probably by an enzymic process which prevents the accumulation of lipid peroxides on LDL. Paraoxonase is an example of an enzyme which might possibly be involved.
-
serum Paraoxonase activity in familial hypercholesterolaemia and insulin dependent diabetes mellitus
Atherosclerosis, 1991Co-Authors: Michael I Mackness, S Arrol, D W S Harty, D Bhatnagar, Peter Winocour, Monica Ishola, Paul N DurringtonAbstract:The activity of serum Paraoxonase, an enzyme located on high-density lipoprotein, has been investigated in familial hypercholesterolaemia (FH) and insulin dependent diabetes mellitus (IDDM). Increases in total serum cholesterol and apolipoprotein B were present in both FH and IDDM compared to healthy controls and in the patients with IDDM, serum triglycerides were also raised. The serum HDL-cholesterol concentrations in controls and patients with FH and IDDM did not differ significantly. Serum Paraoxonase activity was significantly lower in both the FH and IDDM populations than in controls (P < 0.001 and P < 0.01, respectively). 72% of the FH population and 67% of the IDDM population were in the lower half of the frequency distribution for serum Paraoxonase (activity of < 112 U/l). It is likely that the common factor related to low Paraoxonase activity is hyperlipidaemia. It is possible that Paraoxonase has a physiological role in lipid metabolism and that decreases in its activity may accelerate atherogenesis.
Hakim Celik - One of the best experts on this subject based on the ideXlab platform.
-
Paraoxonase and Arylesterase Activities in Children With Iron Deficiency Anemia and Vitamin B12 Deficiency Anemia
Pediatric hematology and oncology, 2012Co-Authors: Ahmet Koç, Murad Cengiz, Zeynep Canan Ozdemir, Hakim CelikAbstract:Paraoxonase-1 is an esterase enzyme and it has 3 types of activity, namely Paraoxonase, arylesterase, and diazoxonase. It has been reported that Paraoxonase-1 deficiency is related to increased susceptibility to development of atherosclerosis and cardiovascular disease. The aim of this study was to investigate serum Paraoxonase and arylesterase activities in children with iron deficiency anemia and vitamin B(12) deficiency anemia. Thirty children with iron deficiency anemia, 30 children with vitamin B(12) deficiency anemia, and 40 healthy children aged 6 months to 6 years were enrolled in this study. Serum Paraoxonase and arylesterase activities were measured with a spectrophotometer by using commercially available kits. Mean Paraoxonase and arylesterase activities in vitamin B(12) deficiency anemia group (103 ± 73 and 102 ± 41 U/L, respectively) were significantly lower than mean activities of control group (188 ± 100 and 147 ± 34 U/L, respectively; P .05). Paraoxonase and arylesterase activities significantly increased after treatment with vitamin B(12) in vitamin B(12) deficiency anemia; however, there were no significant changes in the activities of these enzymes after iron treatment in iron deficiency anemia group. Important correlations were found between vitamin B(12) levels and both Paraoxonase and arylesterase activities (r = .367, P < .001; r = .445, P < .001). Our results suggest that vitamin B(12) deficiency anemia causes important reductions in Paraoxonase and arylesterase activities, and after vitamin B(12) therapy the activities of these enzymes returned to near-normal levels.
-
decreased Paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus
Journal of Womens Health, 2009Co-Authors: Hakan Camuzcuoglu, Harun Toy, Hale Cakir, Hakim Celik, Ozcan ErelAbstract:Abstract Objective: The aim of this study was to investigate serum Paraoxonase, arlyesterase activities, and lipid hydroperoxide (LOOH) levels in patients with gestational diabetes mellitus (GDM). Methods: Paraoxonase and arylesterase activities, and LOOH levels were assessed for GDM cases (n = 55) and controls (n = 59). Serum basal and salt-stimulated Paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by ferrous oxidation with a xylenol orange assay. Results: Basal and salt-stimulated Paraoxonase and arylesterase activities were significantly lower (p = 0.002, p = 0.004; and p = 0.013, respectively) in patients with GDM compared to controls, while LOOH levels were significantly higher (p < 0.001). Among gestational diabetes patients, serum Paraoxonase and arylesterase activities were inversely correlated with LOOH levels (r = − 0.390, p = 0.003; and r = − 0.287, p = 0.034, respectively). Conclusions: Findings of the present study have shown that serum ...
-
Decreased Paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus.
Journal of women's health (2002), 2009Co-Authors: Hakan Camuzcuoglu, Harun Toy, Hale Cakir, Hakim Celik, Ozcan ErelAbstract:Abstract Objective: The aim of this study was to investigate serum Paraoxonase, arlyesterase activities, and lipid hydroperoxide (LOOH) levels in patients with gestational diabetes mellitus (GDM). Methods: Paraoxonase and arylesterase activities, and LOOH levels were assessed for GDM cases (n = 55) and controls (n = 59). Serum basal and salt-stimulated Paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by ferrous oxidation with a xylenol orange assay. Results: Basal and salt-stimulated Paraoxonase and arylesterase activities were significantly lower (p = 0.002, p = 0.004; and p = 0.013, respectively) in patients with GDM compared to controls, while LOOH levels were significantly higher (p
-
Assessment of Paraoxonase activities in patients with knee osteoarthritis.
Redox report : communications in free radical research, 2008Co-Authors: Neslihan Soran, Hale Cakir, Hakim Celik, Ozlem Altindag, Ahmet Demirkol, Nurten AksoyAbstract:The objective of this study was to investigate serum Paraoxonase and arylesterase activities, and lipid hydroperoxide (LOOH) and total thiol (total free sulfhydryl groups, -SH) levels along with lipid parameters in patients with knee osteoarthritis. Thirty-six patients with knee osteoarthritis and 30 healthy individuals were enrolled in the study. Serum Paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by ferrous oxidation with xylenol orange assay (FOX-2). Serum high-density lipoprotein-cholesterol (HDL-C), -SH levels, Paraoxonase and arylesterase activities were significantly lower in the patient group than those in the controls (P < 0.05, for all), while LOOH and low-density lipoprotein (LDL) levels were significantly higher. In conclusion, Paraoxonase and arylesterase activities were decreased significantly in patients with knee osteoarthritis. Lower serum Paraoxonase-1 activity and lower level of HDL-C seem to be related to increased oxidative stress and inflammatory condition in these patients. It is known that Paraoxonases reduce oxidative stress in serum and tissues thereby protecting against cardiovascular disease, particularly atherosclerosis. Thus, decreased Paraoxonase and arylesterase activities play a role in the pathogenesis of atherosclerosis through increased susceptibility to lipid peroxidation in patients with osteoarthritis.
-
Assessment of Paraoxonase and arylesterase activities in patients with iron deficiency anemia.
Atherosclerosis, 2006Co-Authors: Mehmet Aslan, Hakim Celik, Mustafa Kosecik, Mehmet Horoz, Sahbettin Selek, Ozcan ErelAbstract:Abstract Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL) associated enzyme with three activities which are Paraoxonase, arylesterase and dyazoxonase. We aimed to determine serum (a) Paraoxonase and arylesterase activities and, lipid hydroperoxide (LOOH) levels in patients with iron deficiency anemia (IDA) (b) whether there is an association between the development of atherosclerosis and Paraoxonase/arylesterase activities in patients with IDA. Twenty-five female with IDA and 22 healthy female as control were enrolled in the study. Serum basal/salt-stimulated Paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by ferrous oxidation with xylenol orange assay. Basal/salt-stimulated Paraoxonase and arylesterase activities were significantly lower in patients with IDA than controls ( p p
Mehmet Aslan - One of the best experts on this subject based on the ideXlab platform.
-
Paraoxonase and arylesterase activities in untreated dipper and non dipper hypertensive patients
Clinical Biochemistry, 2008Co-Authors: Ali Yildiz, Mehmet Aslan, Recep Demirbag, Mustafa Gur, Remzi Yilmaz, Selahattin Akyol, Ozcan ErelAbstract:Objectives Paraoxonase, a high density lipoprotein (HDL) associated enzyme, was shown to be reduced in patients with cardiovascular diseases. We aimed to examine serum Paraoxonase and arylesterase activities, and oxidative stress markers such as lipid hydroperoxide (LOOH) and total antioxidant status (TAS) in dipper and non-dipper hypertensive patients. Design and methods Forty-six non-dipper hypertensives (NDH group), 40 dipper hypertensives (DH group) and 28 healthy control subjects were included in the study. Clinical and echocardiographic assessment and ambulatory blood pressure monitoring were performed in all subjects. Serum Paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by ferrous oxidation with xylenol orange assay. TAS was determined by using an automated measurement method. Results Paraoxonase and arylesterase activities and TAS levels were significantly lower in patients with NDH compared to both DH and control groups (p < 0.001, for both). Also, LOOH levels were found at high level in patients with NDH compared to control and DH groups. In NDH group, both Paraoxonase and arylesterase activities were independently correlated with LDL cholesterol, TAS and LOOH levels. In DH group, both Paraoxonase and arylesterase activities were independently correlated with HDL cholesterol and LOOH levels. Conclusions Reduced Paraoxonase and arylesterase activities in NDH might indicate increased oxidative stress, which plays an important role in the development of cardiovascular diseases. Low serum activities of Paraoxonase and arylesterase might be considered as prospective prognostic markers of the development of cardiovascular diseases in dipper and non-dipper hypertensive patients.
-
Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients.
Clinical biochemistry, 2008Co-Authors: Ali Yildiz, Mehmet Aslan, Recep Demirbag, Mustafa Gur, Remzi Yilmaz, Selahattin Akyol, Ozcan ErelAbstract:Paraoxonase, a high density lipoprotein (HDL) associated enzyme, was shown to be reduced in patients with cardiovascular diseases. We aimed to examine serum Paraoxonase and arylesterase activities, and oxidative stress markers such as lipid hydroperoxide (LOOH) and total antioxidant status (TAS) in dipper and non-dipper hypertensive patients. Forty-six non-dipper hypertensives (NDH group), 40 dipper hypertensives (DH group) and 28 healthy control subjects were included in the study. Clinical and echocardiographic assessment and ambulatory blood pressure monitoring were performed in all subjects. Serum Paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by ferrous oxidation with xylenol orange assay. TAS was determined by using an automated measurement method. Paraoxonase and arylesterase activities and TAS levels were significantly lower in patients with NDH compared to both DH and control groups (p<0.001, for both). Also, LOOH levels were found at high level in patients with NDH compared to control and DH groups. In NDH group, both Paraoxonase and arylesterase activities were independently correlated with LDL cholesterol, TAS and LOOH levels. In DH group, both Paraoxonase and arylesterase activities were independently correlated with HDL cholesterol and LOOH levels. Reduced Paraoxonase and arylesterase activities in NDH might indicate increased oxidative stress, which plays an important role in the development of cardiovascular diseases. Low serum activities of Paraoxonase and arylesterase might be considered as prospective prognostic markers of the development of cardiovascular diseases in dipper and non-dipper hypertensive patients.
-
serum Paraoxonase and arylesterase activities for the evaluation of patients with chronic hepatitis
International Journal of Clinical Practice, 2007Co-Authors: Mehmet Aslan, Mehmet Horoz, Sahbettin Selek, Yasar Nazligul, Cengiz Bolukbas, Filiz F Bolukbas, Nurten Aksoy, Ozcan ErelAbstract:Summary The sensitivity of standard biochemical tests for liver function is low and insufficient for a reliable determination of the presence or absence of liver disease. The aim of the present study was to investigate serum Paraoxonase and arylesterase activities and lipid hydroperoxide (LOOH) levels, and to find out that whether the measurement of serum Paraoxonase and arylesterase activities would be useful as an index of liver function status in chronic hepatitis (CH). Fourty-four patients with CH (24 CHB and 20 CHC) and 38 controls were enrolled. Serum Paraoxonase and arylesterase activities were detected spectrophotometrically. LOOH levels were measured by the FOX-2 assay. Serum Paraoxonase and arylesterase activities were significantly lower in patients with CH than controls (p < 0.001 for both), while LOOH levels were significantly higher (p < 0.001). Paraoxonase and arylesterase activities were inversely correlated with LOOH levels (r = −0.394, p < 0.05; r =−0.362, p < 0.05, respectively). Fibrosis scores of CH patients were significantly correlated with Paraoxonase and arylesterase activities and LOOH levels (r =−0.276, p < 0.05; r = −0.583, p < 0.001 and r = 0.562, p < 0.001, respectively). Our results indicated that decrease in the activities Paraoxonase and arylesterase may play a role in the pathogenesis of CH. In addition, serum Paraoxonase and arylesterase activities measurement may add a significant contribution to the liver function tests.
-
Paraoxonase and arylesterase activities in patients with cardiac syndrome x and their relationship with oxidative stress markers
Coronary Artery Disease, 2007Co-Authors: Mustafa Gur, Mehmet Aslan, Recep Demirbag, Ali Yildiz, Remzi Yilmaz, Ibrahim Ozdogru, Ozcan ErelAbstract:OBJECTIVES Paraoxonase-1 is a high-density lipoprotein-associated enzyme with three activities, which are Paraoxonase, arylesterase and dyazoxonase. Paraoxonase-1 was shown to decrease in patients with cardiovascular diseases. We aimed to examine serum Paraoxonase and arylesterase activities, and their relation with oxidative stress markers such as lipid hydroperoxide and total antioxidant status in patients with cardiac syndrome X. METHODS Forty-one consecutive patients with cardiac syndrome X (CSX group), 33 consecutive patients without cardiac syndrome X (non-cardiac syndrome X group) and 20 healthy volunteers as control group were taken into the study. Serum Paraoxonase and arylesterase activities were measured spectrophotometrically. Lipid hydroperoxide levels were measured by ferrous oxidation with xylenol orange assay. Total antioxidant status was determined using an automated measurement method. RESULTS Basal Paraoxonase, salt-stimulated Paraoxonase and arylesterase activities were significantly lower in patients with cardiac syndrome X than those of the non-cardiac syndrome X and control groups (P<0.001, for both). Moreover, lipid hydroperoxide was found at high level, and total antioxidant status was found at low level in patients with cardiac syndrome X than control and non-cardiac syndrome X groups (P<0.001, for all). In patients with cardiac syndrome X, in multiple linear regression analysis, both Paraoxonase and arylesterase activities were independently correlated with lipid hydroperoxide levels (P=0.001, P=0.003, respectively), and also arylesterase activity was independently correlated with magnitude of ST depression (P=0.002). CONCLUSION Reduced Paraoxonase and arylesterase activities and total antioxidant status levels and enhanced lipid hydroperoxide levels in patients with cardiac syndrome X might indicate increased oxidative stress that can play a role in pathogenesis of cardiac syndrome X.
-
Paraoxonase and arylesterase activities in patients with cardiac syndrome X, and their relationship with oxidative stress markers.
Coronary artery disease, 2007Co-Authors: Mustafa Gur, Mehmet Aslan, Recep Demirbag, Ali Yildiz, Remzi Yilmaz, Ibrahim Ozdogru, Ozcan ErelAbstract:OBJECTIVES Paraoxonase-1 is a high-density lipoprotein-associated enzyme with three activities, which are Paraoxonase, arylesterase and dyazoxonase. Paraoxonase-1 was shown to decrease in patients with cardiovascular diseases. We aimed to examine serum Paraoxonase and arylesterase activities, and their relation with oxidative stress markers such as lipid hydroperoxide and total antioxidant status in patients with cardiac syndrome X. METHODS Forty-one consecutive patients with cardiac syndrome X (CSX group), 33 consecutive patients without cardiac syndrome X (non-cardiac syndrome X group) and 20 healthy volunteers as control group were taken into the study. Serum Paraoxonase and arylesterase activities were measured spectrophotometrically. Lipid hydroperoxide levels were measured by ferrous oxidation with xylenol orange assay. Total antioxidant status was determined using an automated measurement method. RESULTS Basal Paraoxonase, salt-stimulated Paraoxonase and arylesterase activities were significantly lower in patients with cardiac syndrome X than those of the non-cardiac syndrome X and control groups (P
